Genomic profiling is a revolutionary oncology tool that allows the genetic profile of a tumor to be analyzed in order to inform targeted cancer treatment. The session "Genomic Profiling" addresses tumor genetics, actionable mutations, and the use of such information for precision medicine.".
By sequencing RNA and DNA of a tumor, genomic profiling can expose mutations, copy number aberrations, gene fusions, and other alterations that propel cancer development. Based on these findings, clinicians can choose targeted therapies, immunotherapies, or combination regimens specifically suited to an individual patient, enhancing efficacy and reducing unnecessary toxicity. New technologies, such as next-generation sequencing (NGS) and whole-exome or whole-genome sequencing, accelerate and deepen the analysis.
The session also discusses the potential of genomic profiling in the prediction of treatment response, monitoring minimal residual disease, and detection of resistance mechanisms. Bioinformatics integration with molecular diagnostics and liquid biopsy methods offers a complete picture of tumor heterogeneity and evolution.
Participants will learn about methodologies, clinical applications, and novel research in genomic profiling. This session highlights how the use of tumor genomic data can maximize treatment choice, enhance patient outcomes, and enhance precision oncology, making this session a must-have in current cancer care.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
